Nuvastatic® for metastatic colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new capsule (Nuvastatic®) added to standard chemotherapy for people with metastatic colorectal cancer. The goal is to see if it helps shrink tumors and improve well-being.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have colorectal cancer that has spread to other parts of the body (metastatic).
- You are scheduled to receive at least 6 cycles of standard chemotherapy.
- You have a tumor that is at least 1 cm in size (visible on a CT or MRI scan).
- You are able to perform daily activities with some help (ECOG performance status 0-2).
- You are not pregnant, breastfeeding, or have a brain infection from cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether Nuvastatic, a natural supplement, can help reduce fatigue in women with triple-negative breast cancer who are about to start chemotherapy. If you have stable or worsening fatigue and meet the other criteria, you may be able to join.
This study tests an oral supplement (Nuvastatic) to see if it helps reduce fatigue in people with stage IV colon cancer who are starting chemotherapy for the first time. If you are 18–65 and have fatigue that is affecting you, this trial might offer a way to feel better.
This trial tests a new immunotherapy drug, nelmastobart, combined with two standard chemotherapy drugs (trifluridine/tipiracil and bevacizumab) for people with advanced colorectal cancer that hasn't responded to other treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
This trial tests a new drug called nuzefatide pevedotin for people with metastatic pancreatic cancer that has progressed after one prior treatment. The drug targets a protein called EphA2 found on some tumor cells and may slow tumor growth.
This study tests a new form of megestrol (a medicine that can boost appetite and energy) for people with advanced stomach or colorectal cancer who also have fatigue and poor appetite. It is given as a first treatment, meaning you haven't had chemotherapy yet for your advanced cancer.
Hear when a new Fatigue Related to Cancer Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.